Australia, 23rd Jul 2026 – Neuralia TMS, a prominent provider of Transcranial Magnetic Stimulation (TMS) therapy based in Como, Western Australia, has announced an extension of treatment access for patients across Australia seeking non-invasive, drug-free options for managing depression. The extension centres on the clinic’s combined delivery model, which pairs in-clinic TMS sessions with at-home transcranial Direct Current Stimulation (tDCS) therapy and pharmacogenetic testing, reducing the need for patients outside the Perth metropolitan area to travel for ongoing care.
The development is relevant to patients in regional and interstate locations who have previously faced logistical barriers to accessing structured mental health treatment, and reflects broader industry attention on making evidence-based, non-drug therapies available beyond major metropolitan clinics.
TMS therapy uses magnetic fields to stimulate nerve cells in regions of the brain associated with mood regulation, and is offered as an alternative for patients who have not responded to standard approaches such as medication or talking therapies. The therapy has been the subject of more than three decades of clinical research and is listed under Medicare for treatment-resistant depression, a status that has applied since November 2021, and is delivered at Neuralia TMS’s Como facility under the oversight of its clinical team. Patients typically begin with an initial clinical assessment before a course of sessions is scheduled, with progress reviewed at regular intervals by the clinical team.
The at-home tDCS option, administered by the patient following clinical guidance, is positioned by the company as a complementary pathway for individuals who require ongoing neuromodulation support between clinic visits or who are unable to attend the Como site on a frequent basis. Patients using the at-home device are provided with instructions and remain in contact with clinical staff for monitoring purposes throughout a course of therapy. Pharmacogenetic testing is also offered to help clinicians tailor treatment plans according to a patient’s individual genetic profile, an approach intended to inform medication selection and reduce the trial-and-error process often associated with treating depression. Test results are incorporated into a patient’s broader treatment plan alongside clinical assessment, rather than used as a standalone diagnostic tool.
“Patients living in regional Western Australia and interstate have indicated that consistent travel to a clinic is not always practical,” said Dr Shanek Wick, Medical Director of Neuralia TMS. “Extending access through a combination of in-clinic and at-home therapy options allows more patients to remain engaged with a treatment plan over time.”
The updated access model applies across Neuralia TMS’s existing service lines, including TMS therapy for depression, anxiety, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), chronic pain and Parkinson’s disease. Referral pathways remain in place through general practitioners, psychiatrists and allied health professionals, consistent with the clinic’s existing intake process. Administrative and clinical scheduling has been adjusted to accommodate patients coordinating between at-home tDCS sessions and periodic in-clinic reviews, with pharmacogenetic testing results incorporated into individual treatment planning where clinically appropriate. The clinic continues to operate from its Como premises, which house treatment rooms, consultation areas and administrative facilities supporting day-to-day operations.
Looking ahead, Dr Wick, said the company expects continued interest in flexible treatment delivery. “The combination of in-clinic and at-home therapy is expected to remain a focus as more patients seek options that fit around work, family and geographic circumstances,” said Dr Wick. “Ongoing monitoring of patient outcomes will guide how these services are adjusted over time.”
Neuralia TMS is based in Como, Western Australia, and provides TMS therapy, at-home tDCS therapy and pharmacogenetic testing for patients experiencing depression, anxiety, PTSD, OCD, chronic pain and Parkinson’s disease. The clinic operates under the oversight of a clinical team led by Dr Shanek Wick, Medical Director, and works alongside referring general practitioners, psychiatrists and allied health professionals across Western Australia. Its services are structured around non-invasive, drug-free approaches to neurological and psychiatric conditions, with treatment plans developed on an individual basis following clinical assessment. The extension of treatment access forms part of the clinic’s ongoing operations, alongside its existing in-clinic and at-home service offerings.info@neuralia.com.au Address: Unit 2A/125 Melville Parade, Marview House, Como WA 6152
For additional information about depression treatment and related industry developments, contact Neuralia TMS at Unit 2A/125 Melville Parade, Marview House, Como WA 6152. Inquiries regarding the clinic’s treatment programs, therapies and patient support services can be directed to 08 6230 3996 or by email at info@neuralia.com.au.
Media Contact
Organization: Neuralia TMS Perth (Como)
Contact Person: Dr. Shanek Wick
Website: https://www.neuraliatms.com.au/
Email: Send Email
Contact Number: +61862303996
Address:Unit 2A/125 Melville Parade
Address 2: Marview House, Como WA 6152
Country:Australia
Release id:47449
The post Neuralia TMS Extends Depression Treatment Access for Australian Patients appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
